Cleantech Leader Aymium Closes $210 Million Financing with Global Investors for Advanced Biocarbon Production Facility in Williams, California
6.6.2024 14:00:00 EEST | Business Wire | Press release
Aymium, the leading producer of renewable biocarbon products, announced today that it closed $210 Million of financing to construct a biocarbon production facility in Williams, California. The facility will support the first large-scale continuous use of advanced biocarbon to replace coal in power generation in the world. Use of the product from the Williams facility to replace coal will reduce greenhouse gas emissions by over 500,000 metric tons per year—equivalent to removing over 120,000 cars from the road annually. Construction of the facility is scheduled to be completed in 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606231738/en/
Aymium's reactor being delivered to the new biocarbon production facility in Williams, CA. The biocarbon will replace coal in power generation around the world and reduce greenhouse gas emissions by more than 500,000 metric tons per year, equivalent to removing 120,000 cars annually. (Photo: Business Wire)
“We are excited to have the support from such an experienced group of investors from Asia, North America and Europe,” said James Mennell, CEO of Aymium. “These groups share a profound commitment to decarbonization and have come together to advance this technology that will create a substantial reduction in greenhouse gas emissions for many years.”
The facility will be funded by a global group of investors dedicated to next-generation decarbonization technologies. Senior debt, in the form of green bonds, will be provided jointly by ECP ForeStar and Copenhagen Infrastructure Partners (CIP) through its Green Credit Fund. Subordinated debt will be provided by Japan Green Investment Corp. for Carbon Neutrality (“JICN”) and Aymium. Equity for the project will come from Hokuriku Electric Power Company, Nippon Steel Trading, and Aymium.
U.S. Ambassador to Japan Rahm Emanuel said: “A global threat like climate change demands a global solution. The only way to tackle a challenge of this magnitude is by thinking and collaborating across borders. With the United States and Japan cooperating on a multitude of areas related to energy and the environment, Aymium’s groundbreaking biocarbon production facility is the latest project to benefit from this flourishing relationship.”
Reiner Boehning, Managing Partner of ECP ForeStar said: “Aymium, together with its partners, has developed a proven production process that is an important building block to help decarbonize industrial processes, like steel making, and power generation. We are thrilled to be part of the investor group that finances the construction of Aymium’s next production facility in Williams, California.”
Jakob Groot, Partner at CIP and co-head of its Green Credit Fund, said: “We are proud to be part of this experienced lending consortium that is supporting Aymium in financing the construction of the Williams project and Hokuriku Electric in their continued decarbonization efforts. This financing represents an attractive opportunity for us and our investors to make yet another meaningful contribution to the green transition.”
Aymium produces the only commercially demonstrated carbon-negative product for replacing coal in power generation. Aymium’s renewable product is created through a non-combustion process that converts waste biomass to high purity biocarbon. The product is specifically engineered to immediately replace fossil coal without the need for any type of plant investment or process modification. The product has superior energy value, handling, and environmental attributes to coal. The process uses third-party certified sustainable waste biomass and is powered by self-generated renewable energy. Aymium’s process and product technologies are protected by more than 500 issued and pending patents. Aymium’s investors include Hokuriku Electric, Nippon Steel Trading, Rio Tinto and Steel Dynamics. Morgan Stanley served as debt arranger to Aymium in this transaction.
About Aymium
Aymium produces high-value biocarbon and biohydrogen products that can be used to immediately replace fossil fuels in the production of energy, metals, crops, and in the purification of water and air with no modifications to equipment or processes. Produced using sustainably sourced biomass – recovered and unusable wood – Aymium’s bioproducts are renewable, carbon-negative and they replace emission-heavy fossil fuels such as coal and coke. Aymium’s leading technology is backed by more than 500 issued or pending patents on a global basis. Aymium is headquartered in Minnesota, USA.
About Hokuriku Electric Power Company
Established in 1951, Hokuriku Electric Power Company is a comprehensive energy company that aims to contribute to the development of the Hokuriku region through the stable supply of affordable and high-quality energy. The company's vision for the future is to “develop together with Hokuriku and deliver new value nationwide and overseas,” and it is expanding its business beyond the existing electric power business while contributing to social issues such as addressing the global warming, sustainable development of the region, and the realization of a smart society.
About Copenhagen Infrastructure Partners
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focus on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.
CIP manages 12 funds and has to date raised approximately EUR 28 billion for investments in energy and associated infrastructure from more than 160 international institutional investors. CIP has approximately 500 employees and 12 offices around the world. For more information, visit www.cip.com.
About Japan Green Investment Corp. for Carbon Neutrality
Japan Green Investment Corp. for Carbon Neutrality (“JICN”) is a fund established through public-private partnership of the Japanese Government and Japanese private institutions, headquartered in Tokyo, JAPAN. JICN provides financing in the form of preferred equity investment and mezzanine or subordinated loans for startups and projects that contribute to the carbon neutrality as well as virtuous cycle between the environment and the economy.
About Nippon Steel Trading
Nippon Steel Trading Corporation is the core trading company of NIPPON STEEL CORPORATION Group, and was established in October 2013 through the merger of Nippon Steel Trading Co., Ltd. and Sumikin Bussan Corporation. The company continues to grow as a multiple specialty trading company operating four integrated core businesses: Steel, Industrial Supply & Infrastructure, Textiles, and Foodstuffs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606231738/en/
Contact information
Scott Gallagher, sgallagher@gardcommunications.com, 503-552-5003
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
